Do analysts prefer ZIVO or ENTX?

Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 403.92%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts clearly believe Entera Bio is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entera Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ZIVO or ENTX more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Entera Bio N/A -83.31% -70.83%

Do analysts recommend ZIVO or CLNN?

Clene has a consensus price target of $33.25, suggesting a potential upside of 450.04%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable earnings and valuation, ZIVO or CLNN?

ZIVO Bioscience has higher earnings, but lower revenue than Clene. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIVO Bioscience $15.85K 1,136.89 -$7.78M -$1.71 N/A Clene $200K 386.28 -$26.17M -$3.20 N/A

Is ZIVO or CLNN more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% Clene -25,009.70% N/A -137.98%

Do analysts recommend SCLX or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, SCLX or ZIVO?

ZIVO Bioscience has lower revenue, but higher earnings than Scilex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scilex $30.25M 2.56 -$358.73M -$40.47 N/A ZIVO Bioscience $15.85K 1,136.89 -$7.78M -$1.71 N/A

Is SCLX or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Scilex -1,110.17% N/A -143.55% ZIVO Bioscience N/A N/A -2,240.92%

Do analysts recommend LFVN or ZIVO?

Lifevantage presently has a consensus target price of $5.00, indicating a potential downside of 19.42%. Given Lifevantage's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lifevantage is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, LFVN or ZIVO?

Lifevantage has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lifevantage $228.53M 0.34 $9.81M $0.45 13.79 ZIVO Bioscience $15.85K 1,136.89 -$7.78M -$1.71 N/A

Do analysts rate ZIVO or HRTX?

Heron Therapeutics has a consensus price target of $2.50, indicating a potential upside of 464.33%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

ZIVO Bioscience (ZIVO) Competitors

$4.34 -0.49 (-10.13%)

As of 02:58 PM Eastern

Compare

ZIVO vs. ENTX, CLNN, SCLX, LFVN, and HRTX

Should you buy ZIVO Bioscience stock or one of its competitors? MarketBeat compares ZIVO Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ZIVO Bioscience include Entera Bio (ENTX), Clene (CLNN), Scilex (SCLX), Lifevantage (LFVN), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry.

How does ZIVO Bioscience compare to Entera Bio?

ZIVO Bioscience (NASDAQ:ZIVO) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

ZIVO Bioscience's return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Entera Bio	N/A	-83.31%	-70.83%

ZIVO Bioscience has higher revenue and earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A
Entera Bio	N/A	N/A	-$11.44M	-$0.27	N/A

ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Entera Bio has a consensus price target of $9.00, suggesting a potential upside of 403.92%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts clearly believe Entera Bio is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entera Bio had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for Entera Bio and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 0.00 beat Entera Bio's score of -0.10 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Entera Bio	Neutral

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 10.6% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Entera Bio beats ZIVO Bioscience on 8 of the 14 factors compared between the two stocks.

How does ZIVO Bioscience compare to Clene?

ZIVO Bioscience (NASDAQ:ZIVO) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

In the previous week, Clene had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Clene and 0 mentions for ZIVO Bioscience. Clene's average media sentiment score of 1.13 beat ZIVO Bioscience's score of 0.00 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Clene	Positive

Clene has a consensus price target of $33.25, suggesting a potential upside of 450.04%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ZIVO Bioscience has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Clene has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

ZIVO Bioscience has a net margin of 0.00% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Clene	-25,009.70%	N/A	-137.98%

ZIVO Bioscience has higher earnings, but lower revenue than Clene. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A
Clene	$200K	386.28	-$26.17M	-$3.20	N/A

Summary

Clene beats ZIVO Bioscience on 9 of the 15 factors compared between the two stocks.

How does ZIVO Bioscience compare to Scilex?

Scilex (NASDAQ:SCLX) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ZIVO Bioscience has lower revenue, but higher earnings than Scilex. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25M	2.56	-$358.73M	-$40.47	N/A
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

ZIVO Bioscience has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,110.17%	N/A	-143.55%
ZIVO Bioscience	N/A	N/A	-2,240.92%

69.7% of Scilex shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Scilex had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 3 mentions for Scilex and 0 mentions for ZIVO Bioscience. Scilex's average media sentiment score of 0.83 beat ZIVO Bioscience's score of 0.00 indicating that Scilex is being referred to more favorably in the media.

Company	Overall Sentiment
Scilex	Positive
ZIVO Bioscience	Neutral

Scilex has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Summary

Scilex beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does ZIVO Bioscience compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Lifevantage has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$228.53M	0.34	$9.81M	$0.45	13.79
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A

Lifevantage has a net margin of 2.94% compared to ZIVO Bioscience's net margin of 0.00%. Lifevantage's return on equity of 23.89% beat ZIVO Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
ZIVO Bioscience	N/A	N/A	-2,240.92%

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lifevantage presently has a consensus target price of $5.00, indicating a potential downside of 19.42%. Given Lifevantage's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lifevantage is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Lifevantage had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Lifevantage and 0 mentions for ZIVO Bioscience. Lifevantage's average media sentiment score of 1.23 beat ZIVO Bioscience's score of 0.00 indicating that Lifevantage is being referred to more favorably in the media.

Company	Overall Sentiment
Lifevantage	Positive
ZIVO Bioscience	Neutral

Lifevantage has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market.

Summary

Lifevantage beats ZIVO Bioscience on 13 of the 15 factors compared between the two stocks.

How does ZIVO Bioscience compare to Heron Therapeutics?

ZIVO Bioscience (NASDAQ:ZIVO) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Heron Therapeutics had 2 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Heron Therapeutics and 0 mentions for ZIVO Bioscience. Heron Therapeutics' average media sentiment score of 0.56 beat ZIVO Bioscience's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Heron Therapeutics	Positive

ZIVO Bioscience has higher earnings, but lower revenue than Heron Therapeutics. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,136.89	-$7.78M	-$1.71	N/A
Heron Therapeutics	$154.90M	0.54	-$20.19M	-$0.18	N/A

Heron Therapeutics has a consensus price target of $2.50, indicating a potential upside of 464.33%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

ZIVO Bioscience has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. ZIVO Bioscience's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Summary

Heron Therapeutics beats ZIVO Bioscience on 10 of the 16 factors compared between the two stocks.

Get ZIVO Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZIVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZIVO vs. The Competition

Export

Metric	ZIVO Bioscience	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18.02M	$350.71M	$6.76B	$12.66B
Dividend Yield	N/A	N/A	2.68%	8.42%
P/E Ratio	-0.89	N/A	27.10	24.38
Price / Sales	1,136.89	200.02	525.30	91.65
Price / Cash	N/A	22.44	48.59	59.39
Price / Book	-5.36	4.86	10.82	6.32
Net Income	-$7.78M	-$141.03M	$3.59B	$331.55M
7 Day Performance	-17.33%	-3.90%	-1.24%	0.08%
1 Month Performance	17.62%	2.36%	3.11%	-0.74%
1 Year Performance	-67.32%	57.49%	29.11%	20.69%

ZIVO Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZIVO ZIVO Bioscience	N/A	$4.34 -10.1%	N/A	-64.2%	$18.02M	$15.85K	N/A	10	Gap Down
ENTX Entera Bio	1.8678 of 5 stars	$1.63 -4.4%	$9.00 +453.8%	-10.0%	$80.10M	$40K	N/A	20	Short Interest Increase
CLNN Clene	3.7007 of 5 stars	$6.20 -0.9%	$33.25 +436.7%	+66.0%	$79.17M	$200K	N/A	100	News Coverage
SCLX Scilex	0.8089 of 5 stars	$9.27 +0.7%	N/A	+38.6%	$78.66M	$33.86M	N/A	80
LFVN Lifevantage	2.9101 of 5 stars	$6.21 -0.6%	$5.00 -19.5%	-49.9%	$78.17M	$228.53M	13.76	260

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZIVO) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. ENTX, CLNN, SCLX, LFVN, and HRTX

How does ZIVO Bioscience compare to Entera Bio?

Summary

How does ZIVO Bioscience compare to Clene?

Summary

How does ZIVO Bioscience compare to Scilex?

Summary

How does ZIVO Bioscience compare to Lifevantage?

Summary

How does ZIVO Bioscience compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZIVO Bioscience (ZIVO) Competitors

ZIVO vs. ENTX, CLNN, SCLX, LFVN, and HRTX

How does ZIVO Bioscience compare to Entera Bio?

Is ZIVO or ENTX more profitable?

Which has better earnings and valuation, ZIVO or ENTX?

Which has more volatility and risk, ZIVO or ENTX?

Do analysts prefer ZIVO or ENTX?

Does the media prefer ZIVO or ENTX?

Do institutionals and insiders hold more shares of ZIVO or ENTX?

Summary

How does ZIVO Bioscience compare to Clene?

Does the media prefer ZIVO or CLNN?

Do analysts recommend ZIVO or CLNN?

Do insiders & institutionals hold more shares of ZIVO or CLNN?

Which has more risk & volatility, ZIVO or CLNN?

Is ZIVO or CLNN more profitable?

Which has preferable earnings and valuation, ZIVO or CLNN?

Summary

How does ZIVO Bioscience compare to Scilex?

Do analysts recommend SCLX or ZIVO?

Which has preferable valuation & earnings, SCLX or ZIVO?

Is SCLX or ZIVO more profitable?

Do institutionals & insiders believe in SCLX or ZIVO?

Does the media refer more to SCLX or ZIVO?

Which has more volatility and risk, SCLX or ZIVO?

Summary

How does ZIVO Bioscience compare to Lifevantage?

Which has higher valuation and earnings, LFVN or ZIVO?

Is LFVN or ZIVO more profitable?

Do insiders & institutionals believe in LFVN or ZIVO?

Do analysts recommend LFVN or ZIVO?

Does the media favor LFVN or ZIVO?

Which has more risk & volatility, LFVN or ZIVO?

Summary

How does ZIVO Bioscience compare to Heron Therapeutics?

Do insiders and institutionals believe in ZIVO or HRTX?

Does the media prefer ZIVO or HRTX?

Which has higher earnings and valuation, ZIVO or HRTX?

Do analysts rate ZIVO or HRTX?

Is ZIVO or HRTX more profitable?

Which has more volatility and risk, ZIVO or HRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO vs. The Competition

ZIVO Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools